The nation of Zimbabwe has declined a major US health deal worth 367 million US dollars (£272m) over five years because of the United States' demand for confidential biological samples.
The decision came to light after a official document from December was leaked, revealing that President Emmerson Mnangagwa deemed the arrangement was "skewed".
A government spokesperson has since stated that the US was seeking genetic material for research and profit while refused to guarantee the resulting advantages from future vaccines.
"We must now begin the challenging and unfortunate process of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more dialogue to find a deal agreeable to all parties so the nation's vital HIV programme can continue.
Broader Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a court blocked a related health funding agreement after concerns were filed about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had overseen aid for the American government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government agreements to boost openness and accountability.
As per statements, Sixteen African countries have to date agreed to these new agreements, representing more than $18.3bn in new funding.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million currently on HIV treatment through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"Effectively, our nation would supply the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our citizens if a future disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining frameworks previously set up through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage potential global health emergencies.
"This framework is designed to ensure that when a country provides its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," he added.
"We welcome ongoing discussions with our US partners on how future co-operation might be structured in a way that respects the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body expressed it acknowledged the government's concerns, but suggested that negotiations must proceed considering a large portion of the nation's HIV programmes relied on external financing.
"If technical issues exist, such as those involving information security or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," it commented.
The halted deal underscores the continuing debate between receiving much-needed foreign assistance and safeguarding local interests in an ever more data-driven world.